This site is intended for Healthcare Professionals only.

‘Price of Covid-19 treatments from Pfizer, Merck, GSK align with patient benefits’


Share post:

The prices of drugs used to treat Covid-19 for those at risk of serious illness are “reasonably aligned” with how much they help patients, according to a draft report from drug-pricing research organisation the Institute for Clinical and Economic Review (ICER).

The report assessed Pfizer’s Paxlovid and Merck & Co’s molnupiravir — both recently authorized antiviral pills — as well as sotrovimab, an intravenous monoclonal antibody drug developed by GlaxoSmithKline and Vir Biotechnology.

The three treatments — approved on an emergency basis for people with mild-to-moderate Covid-19 deemed at risk of progressing to serious illness — have been purchased by the US government and are being distributed free-of-charge to healthcare providers.

The US government has paid around $530 for a 5-day course of Paxlovid, $700 per five-day course of molnupiravir, and $2,100 for a course of sotrovimab — the lone available antibody treatment shown to work against the now dominant Omicron variant of the virus.

In clinical trials, ICER said molnupiravir cut hospitalisation rates for high-risk patients by 30 per cent, compared with 88 per cent risk reduction for Paxlovid and 79 per cent for sotrovimab.

“Right now the alignment of the price and benefits look reasonable,” ICER president Steve Pearson said.

The Pfizer and Merck drugs are meant to be taken at home, while GSK’s antibody is administered in hospital or infusion centres.


Please enter your comment!
Please enter your name here


Related articles

Pharmacy Closures: Survey reveals 6% report multiple pharmacy shutdowns

The NPA is scheduled to call another #SaveOurPharmacies day of action on 19 September to highlight funding crisis...

Majority of labour voters believe junior doctors are underpaid

Leaders of junior doctors in England are set to begin formal negotiations with the new Labour government on...

Dementia diagnoses in England reach record high, NHS figures reveals

England’s top dementia doctor emphasises that getting a diagnosis is the first step in supporting people living with...

Wes Streeting reaffirms mission to cut NHS waiting lists during Heatherwood Hospital visit

Streeting called the NHS "broken," with millions of patients facing long waits for treatment  Health and Social Care Secretary...